This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, L. E. Articles by Boyd, M. T. Search for Related Content PubMed PubMed Citation Articles by Jones, L. E. Articles by Boyd, M. T.

Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer

Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival

¹ Department of Surgery, University of Liverpool, Liverpool, United Kingdom, and ² Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom

Purpose: To enable the design of improved inhibitors of matrix metalloproteinases (MMPs) for the treatment of pancreatic cancer, the expression profiles of a range of MMPs and tissue inhibitors of MMPs (TIMPs) were determined.

Experimental Design: Nine MMPs (MMPs 1–3, 7–9, 11, 12, and 14) and three TIMPs (TIMPs 1–3) were examined in up to 75 pancreatic ductal adenocarcinomas and 10 normal pancreata by immunohistochemistry. Eighteen additional pancreatic ductal adenocarcinomas and an additional eight normal pancreata were also analyzed by real-time reverse transcription-PCR and additionally for MMP-15.

Results: There was increased expression by immunohistochemistry for MMPs 7, 8, 9, and 11 and TIMP-3 in pancreatic cancer compared with normal pancreas (P < 0.0001, 0.04, 0.0009, 0.005, and 0.0001, respectively). Real-time reverse transcription-PCR showed a significant increase in mRNA levels for MMP-11 in tumor tissue compared with normal pancreatic tissue (P = 0.0005) and also significantly reduced levels of MMP-15 (P = 0.0026). Univariate analysis revealed that survival was reduced by lymph node involvement (P = 0.0007) and increased expression of MMP-7 (P = 0.005) and (for the first time) MMP-11 (P = 0.02) but not reduced by tumor grade, tumor diameter, positive resection margins, adjuvant treatment, or expression of the remaining MMPs and TIMPs. On multivariate analysis, only MMP-7 predicted shortened survival (P < 0.05); however, increased MMP-11 expression was strongly associated with lymph node involvement (P = 0.0073).

Conclusions: We propose that the principle specificity for effective inhibitors of MMPs in pancreatic cancer should be for MMP-7 with secondary specificity against MMP-11. Moreover, these studies indicate that MMP-7 expression is a powerful independent prognostic indicator and potentially of considerable clinical value.

This article has been cited by other articles:

				D. Peruzzi, F. Mori, A. Conforti, D. Lazzaro, E. De Rinaldis, G. Ciliberto, N. La Monica, and L. Aurisicchio MMP11: A Novel Target Antigen for Cancer Immunotherapy Clin. Cancer Res., June 15, 2009; 15(12): 4104 - 4113. [Abstract] [Full Text] [PDF]

				S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]

				Y. Yokoyama, F. Grunebach, S. M. Schmidt, A. Heine, M. Hantschel, S. Stevanovic, H.-G. Rammensee, and P. Brossart Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells Clin. Cancer Res., September 1, 2008; 14(17): 5503 - 5511. [Abstract] [Full Text] [PDF]

				P Ghaneh, E Costello, and J P Neoptolemos Biology and management of pancreatic cancer Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497. [Full Text] [PDF]

				G. Sarkissian, P. Fergelot, P.-J. Lamy, J.-J. Patard, S. Culine, P. Jouin, N. Rioux-Leclercq, and B. Darbouret Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis Clin. Chem., March 1, 2008; 54(3): 574 - 581. [Abstract] [Full Text] [PDF]

				P. Ghaneh, E. Costello, and J. P Neoptolemos Biology and management of pancreatic cancer Gut, August 1, 2007; 56(8): 1134 - 1152. [Full Text] [PDF]

				K. F.D. Kuhlmann, J.W. O. van Till, M. A. Boermeester, P. R. de Reuver, I. D. Tzvetanova, G. J. A. Offerhaus, F. J.W. ten Kate, O. R.C. Busch, T. M. van Gulik, D. J. Gouma, et al. Evaluation of Matrix Metalloproteinase 7 in Plasma and Pancreatic Juice as a Biomarker for Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 886 - 891. [Abstract] [Full Text] [PDF]

				S. Ueda, K. Fukamachi, Y. Matsuoka, N. Takasuka, F. Takeshita, A. Naito, M. Iigo, D. B. Alexander, M. A. Moore, I. Saito, et al. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas Carcinogenesis, December 1, 2006; 27(12): 2497 - 2510. [Abstract] [Full Text] [PDF]

				Y. Miyata, T. Iwata, K. Ohba, S. Kanda, M. Nishikido, and H. Kanetake Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis Clin. Cancer Res., December 1, 2006; 12(23): 6998 - 7003. [Abstract] [Full Text] [PDF]

				D. Talantov, J. Baden, T. Jatkoe, K. Hahn, J. Yu, Y. Rajpurohit, Y. Jiang, C. Choi, J. S. Ross, D. Atkins, et al. A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of Origin J. Mol. Diagn., July 1, 2006; 8(3): 320 - 329. [Abstract] [Full Text] [PDF]

				M. Ii, H. Yamamoto, Y. Adachi, Y. Maruyama, and Y. Shinomura Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis Experimental Biology and Medicine, January 1, 2006; 231(1): 20 - 27. [Abstract] [Full Text] [PDF]

				H.-z. Luo, Z.-g. Zhou, L. Yang, Y.-y. Yu, C. Tian, B. Zhou, X.-L. Zheng, Q.-j. Xia, Y. Li, and R. Wang Clinicopathologic and Prognostic Significance of MMP-7 (Matrilysin) Expression in Human Rectal Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 739 - 744. [Abstract] [Full Text] [PDF]

				J. Zhang, X. Jin, S. Fang, R. Wang, Y. Li, N. Wang, W. Guo, Y. Wang, D. Wen, L. Wei, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma Carcinogenesis, October 1, 2005; 26(10): 1748 - 1753. [Abstract] [Full Text] [PDF]

				P. Modena, E. Lualdi, F. Facchinetti, L. Galli, M. R. Teixeira, S. Pilotti, and G. Sozzi SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas Cancer Res., May 15, 2005; 65(10): 4012 - 4019. [Abstract] [Full Text] [PDF]

				R. Reich, Y. Katz, R. Hadar, and E. Breuer Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 3: In vivo Evaluation of Cyclopentylcarbamoylphosphonic Acid in Experimental Metastasis and Angiogenesis Clin. Cancer Res., May 15, 2005; 11(10): 3925 - 3929. [Abstract] [Full Text] [PDF]